Chondrokin is under clinical development by Meluha Life Sciences and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Chondrokin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Chondrokin is under development for the treatment of osteoarthritis. The therapy comprises of cytokine mixture derived from chondrogen cells.
For a complete picture of Chondrokin’s drug-specific PTSR and LoA scores, buy the report here.